CSC price target raised to $39 from $34 at Stifel Nicolaus Stifel Nicolaus increased its target on CSC after the company reported higher than expected EPS. The firm raised its FY13 EPS estimate to $2.50, the top of the company's guidance. The firm maintains a Buy rating.
CSC legal risks increased with new lawsuit, says Wells Fargo Wells Fargo sees increased legal risks for CSC after the United States Attorney for the Southern District of New York sued the company and the City of New York for Medicaid fraud. Given the legal uncertainty, Wells expects CSC to continue to maintain a "relatively sizable" cash position on the balance sheet for the "foreseeable future." It keeps a Market Perform rating on the stock.